Effect of metformin intervention on circulating irisin levels in polycystic ovary syndrome : a systematic review and collaborative meta-analysis
BACKGROUND: Irisin is an adipo-myokine with potential implications in metabolic disorders such as polycystic ovary syndrome (PCOS). Despite of a strong evidence showing increased irisin level in PCOS, there is no conclusive evidence on the effect of metformin intervention on circulatory irisin in PCOS.
AIM: The aim of this meta-analysis was to compare the circulatory (serum/plasma) irisin levels before and after metformin intervention in subjects with PCOS.
METHODS: Relevant studies were retrieved by online database and manual searching. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. A one-study leave-out sensitivity analysis was conducted to validate the overall obtained results.
RESULTS: A total of five observations were included in this meta-analysis. The results based on random effects meta-analysis indicated that irisin levels were significantly decreased after metformin intervention as compared to the baseline pretreatment levels in PCOS (SMD: -1.00, 95% CI: -1.60 to -0.41, Z: 3.29, p = .001). The sensitivity analysis leaving-out a particular observation at a time and repeating the meta-analysis validated the robustness of the overall finding suggesting the significant effect of metformin treatment on irisin levels in PCOS.
CONCLUSION: Circulating irisin levels were significantly decreased upon metformin intervention in PCOS patients. The higher pretreatment irisin levels in PCOS may recede once the altered metabolic state is restored upon metformin intervention. Well-designed randomized trials with large sample sizes are warranted to further substantiate the reported evidence reported and to establish the possible mechanisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology - 38(2022), 3 vom: 15. März, Seite 207-212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varikasuvu, Seshadri Reddy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 28.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09513590.2021.1998439 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333174461 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333174461 | ||
| 003 | DE-627 | ||
| 005 | 20231225221114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09513590.2021.1998439 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333174461 | ||
| 035 | |a (NLM)34779689 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varikasuvu, Seshadri Reddy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of metformin intervention on circulating irisin levels in polycystic ovary syndrome |b a systematic review and collaborative meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 28.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Irisin is an adipo-myokine with potential implications in metabolic disorders such as polycystic ovary syndrome (PCOS). Despite of a strong evidence showing increased irisin level in PCOS, there is no conclusive evidence on the effect of metformin intervention on circulatory irisin in PCOS | ||
| 520 | |a AIM: The aim of this meta-analysis was to compare the circulatory (serum/plasma) irisin levels before and after metformin intervention in subjects with PCOS | ||
| 520 | |a METHODS: Relevant studies were retrieved by online database and manual searching. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. A one-study leave-out sensitivity analysis was conducted to validate the overall obtained results | ||
| 520 | |a RESULTS: A total of five observations were included in this meta-analysis. The results based on random effects meta-analysis indicated that irisin levels were significantly decreased after metformin intervention as compared to the baseline pretreatment levels in PCOS (SMD: -1.00, 95% CI: -1.60 to -0.41, Z: 3.29, p = .001). The sensitivity analysis leaving-out a particular observation at a time and repeating the meta-analysis validated the robustness of the overall finding suggesting the significant effect of metformin treatment on irisin levels in PCOS | ||
| 520 | |a CONCLUSION: Circulating irisin levels were significantly decreased upon metformin intervention in PCOS patients. The higher pretreatment irisin levels in PCOS may recede once the altered metabolic state is restored upon metformin intervention. Well-designed randomized trials with large sample sizes are warranted to further substantiate the reported evidence reported and to establish the possible mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Irisin | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a polycystic ovary syndrome | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 700 | 1 | |a Pérez-López, Faustino R |e verfasserin |4 aut | |
| 700 | 1 | |a Thangappazham, Balachandar |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, Hemanth |e verfasserin |4 aut | |
| 700 | 1 | |a Vykunta, Alekya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology |d 1996 |g 38(2022), 3 vom: 15. März, Seite 207-212 |w (DE-627)NLM013051202 |x 1473-0766 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:3 |g day:15 |g month:03 |g pages:207-212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09513590.2021.1998439 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 3 |b 15 |c 03 |h 207-212 | ||